Clinical Trials

240 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06504615 2026-04-03

METAGIO

208 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Adenocarcinoma

NCT06487156 2026-01-27

FINN

404 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07141563 2026-01-07

A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC

70 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06452329 2025-12-04

A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

260 enrolled

Stomach Neoplasms

NCT07091695 2025-11-12

Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

Melanoma

NCT06345183 2025-11-06

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

327 enrolled

Genitourinary

Advanced Renal Cell Carcinoma (aRCC)

NCT07215962 2025-10-14

Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

300 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06771674 2025-09-09

Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

662 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT04050761 2025-07-02

ProNiHN

502 enrolled

Head & Neck

Head and Neck Neoplasms

NCT07024862 2025-06-17

Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

Carcinoma, Non-Small-Cell Lung

NCT06421311 2025-06-05

URADJ

Terminated

176 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06499298 2025-05-31

Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer

64 enrolled

Esophageal Neoplasms

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04146324 2025-01-24

An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia

150 enrolled

Melanoma

NCT06735781 2024-12-16

Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France

101 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06163170 2024-04-18

A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma

Melanoma

NCT06361563 2024-04-12

Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada

250 enrolled

Gastrointestinal Neoplasms

NCT06361576 2024-04-12

Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada

700 enrolled

Gastrointestinal Neoplasms

NCT04291755 2024-04-05

Development and Analysis of a Stool Bank for Cancer Patients

Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT05611229 2023-04-06

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

1,975 enrolled

Melanoma

NCT05714371 2023-02-06

Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

618 enrolled

Melanoma

NCT04936399 2022-05-25

A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom

87 enrolled

Esophageal Squamous Cell Carcinoma

NCT05068609 2022-05-05

VOLUME-PRO

509 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT04860076 2021-04-26

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

400 enrolled

DermatologicThoracic

Lung Neoplasms, Melanoma

NCT04136470 2020-08-10

BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics

130 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms

NCT04145232 2020-08-10

AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.

30 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04169867 2019-11-20

Polish Microbiome Map

1,160 enrolled

Melanoma, Neoplasms

NCT03165409 2017-10-05

Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread

1,828 enrolled